Redeye makes small adjustments to our short-term estimates while increasing the conviction in the long-term case. With an increased risk-free interest rate and positive estimate change, our Base case is now SEK 34 (35) per share. The current share prices offer a good entry point at a significant discount to the fundamental value.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking.